Soltamox is a drug owned by Mayne Pharma Commercial Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 26, 2018. Details of Soltamox's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6127425 | Oral liquid medicine solution |
Jun, 2018
(6 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Soltamox is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Soltamox's family patents as well as insights into ongoing legal events on those patents.
Soltamox's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Soltamox's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 26, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Soltamox Generic API suppliers:
Tamoxifen Citrate is the generic name for the brand Soltamox. 12 different companies have already filed for the generic of Soltamox, with Actavis Labs Fl Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Soltamox's generic
About Soltamox
Soltamox is a drug owned by Mayne Pharma Commercial Llc. Soltamox uses Tamoxifen Citrate as an active ingredient. Soltamox was launched by Mayne Pharma Commrcl in 2005.
Approval Date:
Soltamox was approved by FDA for market use on 29 October, 2005.
Active Ingredient:
Soltamox uses Tamoxifen Citrate as the active ingredient. Check out other Drugs and Companies using Tamoxifen Citrate ingredient
Dosage:
Soltamox is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 20MG BASE/10ML | SOLUTION | Prescription | ORAL |